Compare INSP & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSP | TLX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.3B |
| IPO Year | 2018 | N/A |
| Metric | INSP | TLX |
|---|---|---|
| Price | $130.44 | $9.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $132.27 | $21.00 |
| AVG Volume (30 Days) | ★ 1.8M | 115.0K |
| Earning Date | 11-03-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.77 | N/A |
| EPS | ★ 1.48 | 0.04 |
| Revenue | ★ $882,622,000.00 | $664,225,558.00 |
| Revenue This Year | $14.97 | N/A |
| Revenue Next Year | $11.81 | N/A |
| P/E Ratio | ★ $88.53 | $284.99 |
| Revenue Growth | 16.81 | ★ 55.35 |
| 52 Week Low | $70.77 | $8.76 |
| 52 Week High | $216.01 | $30.36 |
| Indicator | INSP | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 63.19 | 38.74 |
| Support Level | $132.39 | $9.37 |
| Resistance Level | $147.03 | $10.03 |
| Average True Range (ATR) | 8.60 | 0.25 |
| MACD | 0.20 | -0.00 |
| Stochastic Oscillator | 62.23 | 7.65 |
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.